This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Learn about ATTR-CM and uncover the differences between hereditary and wild-type ATTR-CM

Learn about the red flags that may raise suspicion of and techniques used to diagnose ATTR-CM

Explore a range of educational resources to support the diagnosis of ATTR-CM

Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

The different types of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) falls under the disease group cardiac amyloidosis. The most common types of cardiac amyloidosis, accounting for 95% of cases, are ATTR and Immunoglobulin Light Chain Amyloidosis (AL). It is important to differentiate between ATTR and AL, as they have distinct clinical courses and require different approaches to management.1

There are two types of ATTR-CM – Wild-type ATTR-CM and Hereditary ATTR-CM2,3
​​​​​​​

Building the knowledge: Navigating the ATTR amyloidosis disease landscape

This is a series of animated, educational modules that outline key background information on ATTR amyloidosis. This video reviews the disease landscape, and highlights differences between wild-type ATTR amyloidosis and hereditary ATTR amyloidosis.

Wild-type ATTR-CM

Hereditary ATTR-CM

Wild-type ATTR-CM is idiopathic and is not considered to be a hereditary disease.4 It is thought to account for the majority of all ATTR-CM cases.5

Hereditary ATTR-CM in the UK there are thought to be around 40-50 new cases each year.5

Wild-type ATTR-CM is also known as:4

Hereditary ATTR-CM is also known as:3,10
  • Senile cardiac amyloidosis
  • Senile systemic amyloidosis
  • Age-related amyloidosis
  • Variant ATTR (ATTRv)
  • Mutant ATTR (ATTRm)
  • Familial amyloidosis
| Patient Considerations​​​​​​​
| ​​​​​​​Patient Considerations
  • Ethnicity: predominantly white4
  • Found mostly in men4
  • Symptoms onset typically over the age of 60 years6

  • Wild-type ATTR-CM frequently presents with:
    •  ​​​​​​​Heart failure with preserved ejection fraction4
    • Cardiac arrhythmias, particularly atrial fibrillation7​​​​​​​
    • A history of bilateral carpal tunnel syndrome8
  • Men and women11
  • Age of symptom onset depends on the mutation but may occur as early as 50-60 years6
  • ​​​​​​​Hereditary ATTR-CM frequently presents with:
    • ​​​​​​​Heart failure with preserved ejection fraction11-13
    • A range of neurological symptoms (peripheral and autonomic)11-13
    • Gastrointestinal symptoms11-13​​​​​​​
| Prognosis
| Prognosis
Median survival, from diagnosis: ~3.5 years9
Median survival, from diagnosis: 2-5.5 years 5,14

Explore more

 Learn about the signs and symptoms of ATTR-CM

Learn more

See other educational resources available

Explore more
References:
  1. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017; 84(12 Suppl 3): 12–2.
  2. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009; 120(13): 1203–1212.
  3. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018; 25(4): 215–219
  4. Connors LH, Sam F, Skinner M, et al. Heart failure due to age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016; 133(3): 282–290.
  5. Lane T, Fontana M, Martinez-Naharro A, et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019; 140: 16–26.
  6. Ruberg FL and Berk JL. Transthyretin (TTR) Cardiac Amyloidosis. Circulation. 2012; 126: 1286–1300. 
  7. Pinney JH, Whelan CJ, Petrie A, et al. Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome. J Am Heart Assoc. 2013; 2(2): e000098.
  8. Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018; 72(17): 2040–2050.
  9. Grogan M, Scott CG, Kyle RA, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016; 68(10): 1014–1020.
  10. Tuzovic M, Yang EH, Baas AS, et al. Cardiac Amyloidosis: Diagnosis and Treatment Strategies. Curr Oncol Rep. 2017; 19(7): 46.
  11. Maurer MS, Hanna M, Grogan M, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2016; 68(2): 161–172.
  12. Coelho T, Maurer MS, Suhr OB. THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013;29:63–76.
  13. González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. Rev Esp Cardiol (Engl Ed). 2017;70(11):991‐1004.
  14. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017; 135(14): 1357–1377.
PP-VYN-GBR-0967. March 2022

Quick Links

View a range of educational resources to support the diagnosis of ATTR-CM

Listen to our faculty of expert speakers and download resources including our interactive ATTR-CM Red Flags guide. You can also access and sign up to upcoming virtual events. 

PP-VYN-GBR-0729. May 2021

Explore Educational Resources

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. October 2020

Sign up now

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?